The ROADMAP study for diabetic patients has been conducted in Europe, and the result shows that Olmesartan, antihypertensive agent, helps delay the development of diabetic nephropathy. The findings have been published online in New England Journal of Medicine on March 10, 2011. The paper is entitled “Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes.”

The clinical investigation has been conducted as an international joint research and led by Professor Haller from Hannover, Germany as Chairman and 12 committee members including Professor Sadayoshi Ito at Center for Advanced and Integrated Renal Science (CAIRS), United Centers for Advanced Research and Translational Medicine (Art), Tohoku University Graduate School of Medicine and Professor Shigehiro Katayama at Saitama Medical University from Japan.

More Information (Japanese)  

[Contact]

Professor Sadayoshi Ito

Center for Advanced and Integrated Renal Science (CAIRS),United Centers for Advanced Research and Translational Medicine (Art), Tohoku University Graduate School of Medicine

TEL: +81-22-717-7161

E-mail: ishisho*med.tohoku.ac.jp (Replace * with @)

(Public Relations)

Associate professor Fuji Nagami Public Relations Office of Tohoku University Graduate School of Medicine

TEL +81-22-717-7908, FAX: +81-22-717-8187

E-mail: f-nagami*med.tohoku.ac.jp (Replace * with @)